SESSION TITLE: Late-Breaking Abstracts
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 25, 2016 at 08:45 AM - 10:00 AM
PURPOSE: A proportion of pulmonary arterial hypertension (PAH) patients fail to reach/maintain treatment goals with phosphodiesterase 5 inhibitors (PDE5is). RESPITE investigated whether it is safe, feasible, and beneficial to replace PDE5is with riociguat in PAH patients with inadequate response to PDE5is. This analysis explored the relationship between the nitric oxide (NO) signaling biomarkers cyclic guanosine monophosphate (cGMP, a 2nd messenger that mediates smooth muscle relaxation via protein kinase G) and asymmetric dimethylarginine (ADMA, an inhibitor of NO synthesis), and response to riociguat.